These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21421519)

  • 1. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.
    Rayson D; Payne JI; Abdolell M; Barnes PJ; MacIntosh RF; Foley T; Younis T; Burns A; Caines J
    Clin Breast Cancer; 2011 Mar; 11(1):27-32. PubMed ID: 21421519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain.
    Domingo L; Sala M; Servitja S; Corominas JM; Ferrer F; Martínez J; Macià F; Quintana MJ; Albanell J; Castells X
    Cancer Causes Control; 2010 Aug; 21(8):1155-64. PubMed ID: 20349271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.
    Musolino A; Michiara M; Conti GM; Boggiani D; Zatelli M; Palleschi D; Bella MA; Sgargi P; Di Blasio B; Ardizzoni A
    J Clin Oncol; 2012 Jul; 30(19):2362-8. PubMed ID: 22585698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers.
    Domingo L; Blanch J; Servitja S; Corominas JM; Murta-Nascimento C; Rueda A; Redondo M; Castells X; Sala M
    Eur J Cancer Prev; 2013 Jan; 22(1):21-8. PubMed ID: 22584215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.
    Kirsh VA; Chiarelli AM; Edwards SA; O'Malley FP; Shumak RS; Yaffe MJ; Boyd NF
    J Natl Cancer Inst; 2011 Jun; 103(12):942-50. PubMed ID: 21540443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?
    Biesheuvel C; Czene K; Orgeás CC; Hall P
    Cancer Epidemiol; 2011 Dec; 35(6):545-50. PubMed ID: 21470933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.
    Ejlertsen B; Jensen MB; Rank F; Rasmussen BB; Christiansen P; Kroman N; Kvistgaard ME; Overgaard M; Toftdahl DB; Mouridsen HT;
    J Natl Cancer Inst; 2009 May; 101(10):729-35. PubMed ID: 19436035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
    Lynge E
    APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up.
    Kunkler IH; Kerr GR; Thomas JS; Jack WJ; Bartlett JM; Pedersen HC; Cameron DA; Dixon JM; Chetty U;
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):829-38. PubMed ID: 22197227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias.
    Lawrence G; Wallis M; Allgood P; Nagtegaal ID; Warwick J; Cafferty FH; Houssami N; Kearins O; Tappenden N; O'Sullivan E; Duffy SW
    Breast Cancer Res Treat; 2009 Jul; 116(1):179-85. PubMed ID: 18622697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
    Kennedy CR; Gao F; Margenthaler JA
    J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
    Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
    Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
    Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval breast cancers: prognostic features and survival by subtype and time since screening.
    Porter GJ; Evans AJ; Burrell HC; Lee AH; Ellis IO; Chakrabarti J
    J Med Screen; 2006; 13(3):115-22. PubMed ID: 17007651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
    Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
    Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
    Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of screen-detected breast cancers: results of a population based study.
    Cortesi L; Chiuri VE; Ruscelli S; Bellelli V; Negri R; Rashid I; Cirilli C; Fracca A; Gallo E; Federico M
    BMC Cancer; 2006 Jan; 6():17. PubMed ID: 16430776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cancer registry and clinical data as predictors for breast cancer survival.
    Seppänen J; Heinävaara S; Holli K; Hakulinen T
    Cancer Causes Control; 2008 Dec; 19(10):1299-304. PubMed ID: 18752035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.